Disease · MONDO_0008114
Comparisons in its trials43
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 20 of 43
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Troriluzole - Randomization Phase vs Placebo - Randomization Phase: deaths from any cause | 0 of 122 | 0 of 122 | 244 | NCT03299166 | Trial comparisons |
| Troriluzole - Randomization Phase vs Placebo - Randomization Phase: serious adverse events | 0 of 122 | 0 of 122 | 244 | NCT03299166 | Trial comparisons |
| D-Cycloserine vs Sugar Pill: serious adverse events | 0 of 70 | 0 of 72 | 142 | NCT01404208 | Trial comparisons |
| Cognitive-behavioral Therapy Plus Pill Placebo vs Cognitive-behavioral Therapy Plus D-cycloserine: deaths from any cause | 0 of 72 | 0 of 70 | 142 | NCT01411774 | Trial comparisons |
| Cognitive-behavioral Therapy Plus Pill Placebo vs Cognitive-behavioral Therapy Plus D-cycloserine: serious adverse events | 0 of 72 | 0 of 70 | 142 | NCT01411774 | Trial comparisons |
| CERC-501 vs Placebo: deaths from any cause | 0 of 45 | 0 of 44 | 89 | NCT02218736 | Trial comparisons |
| CERC-501 vs Placebo: serious adverse events | 0 of 45 | 0 of 44 | 89 | NCT02218736 | Trial comparisons |
| Oxytocin vs Placebo: deaths from any cause | 0 of 34 | 0 of 33 | 67 | NCT02671266 | Trial comparisons |
| Oxytocin vs Placebo: serious adverse events | 0 of 34 | 0 of 33 | 67 | NCT02671266 | Trial comparisons |
| Riluzole vs Placebo: serious adverse events | 1 of 30 | 0 of 30 | 60 | NCT00251303 | Trial comparisons |
| Riluzole vs Placebo: Much/Very Much Improved on Clinical Global Impressions - Improvement Score (CGI-I) | 3 of 22 | 4 of 29 | 51 | NCT00251303 | Trial comparisons |
| AFQ056 vs Placebo: serious adverse events | 1 of 26 | 2 of 24 | 50 | NCT01813019 | Trial comparisons |
| Obsessive-compulsive Disorder vs Healthy Controls: deaths from any cause | 0 of 23 | 0 of 18 | 41 | NCT02797808 | Trial comparisons |
| Obsessive-compulsive Disorder vs Healthy Controls: serious adverse events | 1 of 23 | 0 of 18 | 41 | NCT02797808 | Trial comparisons |
| Tolcapone vs Placebo: deaths from any cause | 0 of 20 | 0 of 20 | 40 | NCT03348930 | Trial comparisons |
| Tolcapone vs Placebo: serious adverse events | 0 of 20 | 0 of 20 | 40 | NCT03348930 | Trial comparisons |
| Riluzole vs Placebo: Partial Responders by Yale-Brown Obsessive-Compulsive Scale (Y-BOCS) | 5 of 19 | 2 of 18 | 37 | NCT00523718 | Trial comparisons |
| Riluzole vs Placebo: serious adverse events | 1 of 19 | 1 of 18 | 37 | NCT00523718 | Trial comparisons |
| IVIG vs Placebo: The Degree of Treatment Response is Expected to Correlate With the Percentage Reduction in Antinuclear Antibody Titers Following IVIG Administration. | 8 of 17 | 5 of 18 | 35 | NCT01281969 | Trial comparisons |
| Group A vs Group B: Clinical Responder to Treatment | 6 of 17 | 4 of 18 | 35 | NCT01281969 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0008114/comparisons